Biblio

Author Title [ Type

] Year

Filters: Author is Meijer, Ellen [Clear All Filters]

Journal Article

Sijs-Szabo A, Dinmohamed AG, Versluis J, van der Holt B, Bellido M, Hazenberg MD, van Gelder M, Schaap NPM, Meijer E, van der Wagen LE, et al. Allogeneic Stem Cell Transplantation in Patients >40 Years of Age With Acute Lymphoblastic Leukemia: Reduced Intensity Versus Myeloablative Conditioning. Transplantation. 2023.

Aydin M, de Leeuw DC, Rutten CE, Visser OJ, Tang MWai, van Roessel C, Janssen JJW, Biemond BJ, van de Loosdrecht AA, Hazenberg MD, et al. ATG versus PTCy in matched unrelated donor haematopoietic stem cell transplantations with non-myeloablative conditioning. Br J Haematol. 2023.

Chen J, Labopin M, Pabst T, Zhang X, Jiang E, Tucci A, Cornelissen J, Meijer E, Khevelidze I, Polge E, et al. Autologous stem cell transplantation in adult patients with intermediate-risk acute myeloid leukemia in first complete remission and no detectable minimal residual disease. A comparative retrospective study with haploidentical transplants of the global co. Bone Marrow Transplant. 2023.

Sanz J, Labopin M, Pabst T, Versluis J, van Gorkom G, Meijer E, Gedde-Dahl T, Montoro J, Arcese W, Pérez-Simón JAntonio, et al. Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with acute myeloid leukemia in first complete remission: a study from the Acute Leukemia Working Party. Bone Marrow Transplant. 2023.

Nagler A, Labopin M, Dholaria B, Wu D, Choi G, Aljurf M, Ciceri F, Gedde-Dahl T, Meijer E, Niittyvuopio R, et al. Graft-Versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide versus Cyclosporine A and Methotrexate in Matched Sibling Donor Transplantation. Transplant Cell Ther. 2021.

Van Elssen C, van Gorkom G, Voorter C, Borne Pvon dem, Meijer E, Wieten L, Bos G. Haploidentical transplantation in patients with multiple myeloma making use of natural killer cell alloreactive donors. Ann Hematol. 2020.

Aydin M, Tang MWai, Wondergem MJ, de Leeuw DC, Wegman JJ, Biemond BJ, van de Donk NWCJ, Zweegman S, Meijer E, Nur E. High-dose melphalan in 1 day versus over 2 days followed by autologous stem cell transplantation as consolidation treatment in patients with multiple myeloma. Br J Haematol. 2021.

Garrido HMGarcia, Haggenburg S, Schoordijk MCE, Meijer E, Tanck MWT, Hazenberg MD, Rutten CE, de Bree GJ, Nur E, Meek B, et al. Immunogenicity of a 5-dose pneumococcal vaccination schedule following allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2022.

Sahebi F, Eikema D-J, Koster L, Kröger N, Meijer E, van Doesum JA, Rovira M, Koc Y, Angelucci E, Blaise D, et al. Post-Transplant Cyclophosphamide for Graft vs Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type: A Study from the Chronic Malignancies Working Party of the EBM. Transplant Cell Ther. 2021.

Broers AEC, de Jong CN, Bakunina K, Hazenberg MD, Kooy Mvan Marwij, de Groot M, van Gelder M, Kuball J, van der Holt B, Meijer E, et al. Posttransplant Cyclophosphamide for Prevention of Graft-versus-Host Disease: The Prospective Randomized HOVON-96 Trial. Blood Adv. 2022.

Battipaglia G, Labopin M, Hamladji R-M, Blaise D, Chevallier P, Brissot E, Gerbitz A, Socié G, Afanasyev B, Ciceri F, et al. Post-transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-identical sibling donors: A retrospective analysis from the Acute Leukemia Working Party o. Cancer. 2020.

de Jong G, Janssen JJWM, Biemond BJ, Zeerleder SS, Ossenkoppele GJ, Visser O, Nur E, Meijer E, Hazenberg MD. Survival of early post-hematopoietic stem cell transplantation relapse of myeloid malignancies. Eur J Haematol. 2019.

Sanz J, Labopin M, Choi G, Kulagin A, Peccatori J, Vydra J, Remenyi PPal, Versluis J, Rovira M, Blaise D, et al. Younger unrelated donors may be preferable over HLA match in the PTCy era: A study from the ALWP of the EBMT. Blood. 2024.